Table 1 Baseline characteristics of tumor, stratified by patient, treatment and response post-COVID-19 infection/vaccine
Case n° | Pathology | Patient age (years)/Sex | Treatment | Covid-19/ Vaccine | Follow-up | References |
|---|---|---|---|---|---|---|
1 | Classical hodgkin lymphoma | 61/Male | No corticosteroid or immune-chemo-therapy was administered. | Covid-19 | Four months after COVID-19 diagnosis: complete remission | [11] |
2 | Acute myeloid leukemia | 57/Female | NO chemotherapy for AML. COVID-19 was treated with remdesivir at 200 mg intravenously (IV) on the first day, followed by 100 mg daily for 5 days and dexamethasone IV at 8 mg daily for 10 days. Trasfusion with six units of packed red blood cells and ten units of platelets. Pirfenidone, colchicine (0.6 mg twice daily), and oxygen therapy | Covid-19 | Six months after, diagnosis of COVID-19complete remission after 8 months later relapse | [12] |
3 | Acute myeloid leukemia | 63/Female | Postpone treatment protocol. Supportive therapy only (Fluconazole 150 mg 3 times daily/Azithromycin 500 mg daily and Prednisone 100 mg for 5 days) | Covid-19 | After 5 weeks from COVID-19 diagnosis remission and one year later no evidence of disease | [13] |
4 | T-ALL | 28/Male | COVID-19 supportive treatment (Azithromycin 500 mg/day and Prednisone 40 mg daily for 5 days) | Covid-19 | After 6 weeks diagnosis of COVID-19: no evidence of disease | [13] |
5 | Advanced follicular lymphoma | 79/Female | Without lymphoma treatment | Covid-19 | Nine months later diagnosis of COVID-19: complete remission | [14] |
6 | Follicular lymphoma | 61/Male | NA | Covid-19 | After 5 months from diagnosis of COVID-19: complete remission | [15] |
7 | Relapsed/refractory NK/T-cell lymphoma associated with Epstein-Barr virus (EBV) and autoimmune hemolytic anemia (AIHA) | 20/Male | Red-blood cell transfusions and methylprednisolone at rate of 1 mg/kg of body weight per day were administered. No antiviral or cloroquine drugs were administered | Covid-19 | Transient remission of NK lymphoma: remission during COVID-19 infection, followed after 1 month : lymphoma relapse. | [16] |
8 | Multiple myeloma | 76/Female | A single dose of filgrastim, levofloxacin and acyclovir were administered. After the decreasing blood-oxygen levels, the patient was treated with dexamethasone and remdesivir. | Covid-19 | During the next 2 months from COVID-19 diagnosis: no evidence of multiple myeloma | [17] |
9 | Chronic lymphocytic leukaemia (CLL) | 67/Male | Asymptomatic untreated CLL. Multiple treatments including intravenous immunoglobulin and broad-spectrum antibiotics were used for febrile neutropenia | Covid-19 | Complete remission after 12 months of follow-up after diagnosis of COVID-19 | [18] |
10 | Metastatic renal cell carcinoma cancer (mCRC) | 71/Male | Aside from supportive measures, no specific treatment for COVID-19 was administered. | Covid-19 | Follow-up on 6 months from COVID-19 diagnosis: partial regression of metastatic lesions | [19] |
11 | Metastatic renal cell carcinoma cancer (mCRC) | 58/Male | Antibiotics; firstly, clarithromycin and, subsequently, amoxycillin clavulanate for persistent fever. No antineoplastic treatment. | Covid-19 | Four months later COVID-19 diagnosis: reduction in lung metastases | [19] |
12 | Metastatic colorectal cancer (mCRC) | 65/Male | FU/FA/BEVA /depotentiated treatment, with the last cycle performed 1 month before COVID-19 infection | Covid-19 | Follow-up at 18 months: from COVID-19 diagnosis complete response with regression of hepatic lesions | |
13 | Metastatic colorectal cancer (mCRC) | 58/Male | The patient refused post-operative chemotherapy. | Covid-19 | Post COVID-19 infection: reduction of the liver metastatic lesion. Time to-Progression: 23 months | |
14 | Metastatic colorectal cancer (mCRC) | 60/Female | After six cycles with FOLFIRI/PANI, CT scan in September 2020 displayed disease stabilization | Covid-19 | Progression of disease at 2 months from diagnosis of COVID-19 | [21] |
15 | Primary cutaneous anaplastic large-cell lymphoma | 57/Male | NA | COVID-19 vaccination (BionTech/Pfizer) | 1 week before the second dose of COVID-19 vaccination: complete resolution of untreated lymphoma | [22] |
16 | Myoepithelial carcinoma of the left parotid and lung lesion | 61/Female | Close surveillance. | Covid19 vaccination (mRNA-1273) | Persistent tumor shrinkage on follow-up of 9 months, after the second dose of the vaccine. | [23] |